SPARC in cancer biology: Its role in cancer progression and potential for therapy

Drug Resistance Updates

Volumn 11, Issue 6, 2008, Pages 231-246

  Tai, Isabella T ^a,b   Tang, Michelle J ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Albumin binding protein; Chemosensitization; Promoter hypermethylation; SPARC

Indexed keywords

OSTEONECTIN;

ARTICLE; CELL INTERACTION; COLORECTAL CANCER; GLIOMA; HUMAN; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; GENE THERAPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEONECTIN;

EID: 55949136282     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2008.08.005     Document Type: Article

References (141)

1. Abele R., Cavel M., Dodion P., Bruntsch U., Gundersen S., Smyth J., Renard J., van Glabbeke M., and Pinedo H.M. The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. 23 (1987) 1921-1924
2. Ahmed N., Riley C., Oliva K., Stutt E., Rice G.E., and Quinn M.A. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J. Pathol. 201 (2003) 229-237
3. Alonso S.R., Tracey L., Ortiz P., Perez-Gomez B., Palacios J., Pollan M., et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67 (2007) 3450-3460
4. Alvarado C.S., London W.B., Look A.T., Brodeur G.M., Altmiller D.H., Thorner P.S., et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol. 22 (2000) 197-205
5. Alvarez M.J., Prada F., Salvatierra E., Bravo A.I., Lutzky V.P., Carbone C., Pitossi F.J., Chuluyan H.E., and Podhajcer O.L. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res. 65 (2005) 5123-5132
6. Ambros I.M., Zellner A., Roald B., Amann G., Ladenstein R., Printz D., Gadner H., and Ambros P.F. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. New Engl. J. Med. 334 (1996) 1505-1511
7. Arnold S.A., Mira E., Muneer S., Korpanty G., Beck A.W., Holloway S.E., Manes S., and Brekken R.A. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp. Biol. Med. 233 (2008) 860-873
8. Atkinson S.J., Crabbe T., Cowell S., Ward R.V., Butler M.J., Sato H., Seiki M., Reynolds J.J., and Murphy G. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J. Biol. Chem. 270 (1995) 30479-30485
9. Attwell S., Mills J., Troussard A., Wu C., and Dedhar S. Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol. Biol. Cell 14 (2003) 4813-4825
10. Bao W., and Stromblad S. Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J. Cell Biol. 167 (2004) 745-756
11. Barth P.J., Moll R., and Ramaswamy A. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch. 446 (2005) 532-536
12. Beck A.H., Espinosa I., Gilks C.B., van de Rijn M., and West R.B. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab. Invest. 88 (2008) 591-601
13. Bellahcene A., and Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 146 (1995) 95-100
14. Bergamaschi A., Tagliabue E., Sorlie T., Naume B., Triulzi T., Orlandi R., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 214 (2008) 357-367
15. Bornstein P., and Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14 (2002) 608-616
16. Bouzin C., and Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anticancer drug delivery. Drug Resist. Updates 10 (2007) 109-120
17. Bradshaw A.D., and Sage E.H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107 (2001) 1049-1054
18. Brekken R.A., and Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19 (2000) 569-580
19. Brekken R.A., and Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19 (2001) 816-827
20. Brekken R.A., Puolakkainen P., Graves D.C., Workman G., Lubkin S.R., and Sage E.H. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest. 111 (2003) 487-495
21. Briggs J., Chamboredon S., Castellazzi M., Kerry J.A., and Bos T.J. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21 (2002) 7077-7091
22. Brown T.J., Shaw P.A., Karp X., Huynh M.H., Begley H., and Ringuette M.J. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gyn. Oncol. 75 (1999) 25-33
23. Byzova T.V., Kim W., Midura R.J., and Plow E.F. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp. Cell Res. 254 (2000) 299-308
24. Chan S.K., Griffith O.L., Tai I.T., and Jones S.J. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 543-552
25. Cheetham S., Tang M.J., Mesak F., Kennecke H., Owen D., and Tai I.T. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer 98 (2008) 1810-1819
26. Chlenski A., Liu S., Crawford S.E., Volpert O.V., DeVries G.H., Evangelista A., et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 62 (2002) 7357-7363
27. Chlenski A., Liu S., Baker L.J., Yang Q., Tian Y., Salwen H.R., and Cohn S.L. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res. 64 (2004) 7420-7425
28. Chlenski A., Liu S., Guerrero L.J., Yang Q., Tian Y., Salwen H.R., Zage P., and Cohn S.L. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int. J. Cancer 118 (2006) 310-316
29. Clark Jr. W.H., Elder D.E., Guerry D.T., Braitman L.E., Trock B.J., Schultz D., Synnestvedt M., and Halpern A.C. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81 (1989) 1893-1904
30. Cruet-Hennequart S., Maubant S., Luis J., Gauduchon P., Staedel C., and Dedhar S. alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22 (2003) 1688-1702
31. Damjanovski S., Karp X., Funk S., Sage E.H., and Ringuette M.J. Ectopic expression of SPARC in Xenopus embryos interferes with tissue morphogenesis: identification of a bioactive sequence in the C-terminal EF hand. J. Histochem. Cytochem. 45 (1997) 643-655
32. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
33. Dhanesuan N., Sharp J.A., Blick T., Price J.T., and Thompson E.W. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res. Treatm. 75 (2002) 73-85
34. DiMartino J.F., Lacayo N.J., Varadi M., Li L., Saraiya C., Ravindranath Y., Yu R., Sikic B.I., Raimondi S.C., and Dahl G.V. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20 (2006) 426-432
35. Esiri M. Russell and Rubinstein's pathology of tumors of the nervous system. J. Neurol, Neurosurg. Psych. 68 (2000) 538D (6th ed.)
36. Funk S.E., and Sage E.H. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2648-2652
37. Funk S.E., and Sage E.H. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J. Cell. Physiol. 154 (1993) 53-63
38. Giese A., Bjerkvig R., Berens M.E., and Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21 (2003) 1624-1636
39. Gilles C., Polette M., Piette J., Munaut C., Thompson E.W., Birembaut P., and Foidart J.M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer 65 (1996) 209-213
40. Gilles C., Polette M., Seiki M., Birembaut P., and Thompson E.W. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab. Invest. 76 (1997) 651-660
41. Gilles C., Bassuk J.A., Pulyaeva H., Sage E.H., Foidart J.M., and Thompson E.W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 58 (1998) 5529-5536
42. Golembieski W.A., Thomas S.L., Schultz C.R., Yunker C.K., McClung H.M., Lemke N., et al. HSP27 mediates SPARC-induced changes in glioma morphology, migration and invasion. Glia 56 (2008) 1061-1075
43. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005) 7794-7803
44. Haber C.L., Gottifredi V., Llera A.S., Salvatierra E., Prada F., Alonso L., et al. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. Int. J. Cancer 122 (2008) 1465-1475
45. Hasselaar P., and Sage E.H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49 (1992) 272-283
46. Hohenester E., Maurer P., and Timpl R. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J. 16 (1997) 3778-3786
47. Holland P.W., Harper S.J., McVey J.H., and Hogan B.L. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J. Cell Biol. 105 (1987) 473-482
48. Hornebeck W., Emonard H., Monboisse J.C., and Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Sem. Cancer Biol. 12 (2002) 231-241
49. Huang D., Rutkowski J.L., Brodeur G.M., Chou P.M., Kwiatkowski J.L., Babbo A., and Cohn S.L. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res. 60 (2000) 5966-5971
50. Iruela-Arispe M.L., Lane T.F., Redmond D., Reilly M., Bolender R.P., Kavanagh T.J., and Sage E.H. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol. Biol. Cell 6 (1995) 327-343
51. Jones C., Mackay A., Grigoriadis A., Cossu A., Reis-Filho J.S., Fulford L., et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 64 (2004) 3037-3045
52. Kelm Jr. R.J., Hair G.A., Mann K.G., and Grant B.W. Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC). Blood 80 (1992) 3112-3119
53. Kleihues P., Soylemezoglu F., Schauble B., Scheithauer B.W., and Burger P.C. Histopathology, classification and grading of gliomas. Glia 15 (1995) 211-221
54. Koblinski J.E., Kaplan-Singer B.R., VanOsdol S.J., Wu M., Engbring J.A., Wang S., et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res. 65 (2005) 7370-7377
55. Kokenyesi R., Murray K.P., Benshushan A., Huntley E.D., and Kao M.S. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gyn. Oncol. 89 (2003) 60-72
56. Kunigal S., Gondi C.S., Gujrati M., Lakka S.S., Dinh D.H., Olivero W.C., and Rao J.S. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int. J. Oncol. 29 (2006) 1349-1357
57. Kupprion C., Motamed K., and Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273 (1998) 29635-29640
58. Lane T.F., and Sage E.H. Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape. J. Cell Biol. 111 (1990) 3065-3076
59. Lane T.F., Iruela-Arispe M.L., Johnson R.S., and Sage E.H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol. 125 (1994) 929-943
60. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 811-816
61. Ledda F., Bravo A.I., Adris S., Bover L., Mordoh J., and Podhajcer O.L. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 108 (1997) 210-214
62. Ledda M.F., Adris S., Bravo A.I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., and Podhajcer O.L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3 (1997) 171-176
63. Lee S., Hwang K.S., Lee H.J., Kim J.S., and Kang G.H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab. Invest. 84 (2004) 884-893
64. Lien H.C., Hsiao Y.H., Lin Y.S., Yao Y.T., Juan H.F., Kuo W.H., et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26 (2007) 7859-7871
65. Lohi J., and Keski-Oja J. Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J. Biol. Chem. 270 (1995) 17602-17609
66. Lussier C., Sodek J., and Beaulieu J.F. Expression of SPARC/osteonectin/BM4O in the human gut: predominance in the stroma of the remodeling distal intestine. J. Cell. Biochem. 81 (2001) 463-476
67. Martinek N., Zou R., Berg M., Sodek J., and Ringuette M. Evolutionary conservation and association of SPARC with the basal lamina in Drosophila. Dev. Genes Evol. 212 (2002) 124-133
68. Mason I.J., Murphy D., Munke M., Francke U., Elliott R.W., and Hogan B.L. Developmental and transformation-sensitive expression of the Sparc gene on mouse chromosome 11. EMBO J. 5 (1986) 1831-1837
69. Mason I.J., Taylor A., Williams J.G., Sage H., and Hogan B.L. Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of Mr 43.000. EMBO J. 5 (1986) 1465-1472
70. Massi D., Franchi A., Borgognoni L., Reali U.M., and Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol. 30 (1999) 339-344
71. McClung H.M., Thomas S.L., Osenkowski P., Toth M., Menon P., Raz A., et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci. Lett. 419 (2007) 172-177
72. McVey J.H., Nomura S., Kelly P., Mason I.J., and Hogan B.L. Characterization of the mouse SPARC/osteonectin gene. Intron/exon organization and an unusual promoter region. J. Biol. Chem. 263 (1988) 11111-11116
73. Menon P.M., Gutierrez J.A., and Rempel S.A. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int. J. Oncol. 17 (2000) 683-693
74. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153 (1998) 1249-1256
75. Mettouchi A., Cabon F., Montreau N., Vernier P., Mercier G., et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J. 13 (1994) 5668-5678
76. Mok S.C., Chan W.Y., Wong K.K., Muto M.G., and Berkowitz R.S. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12 (1996) 1895-1901
77. Motamed K., and Sage E.H. Regulation of vascular morphogenesis by the matricellular protein SPARC. Kidney Int. 51 (1997) 1383-1387
78. Motamed K., and Sage E.H. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J. Cell. Biochem. 70 (1998) 543-552
79. Murphy-Ullrich J.E., Lane T.F., Pallero M.A., and Sage E.H. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J. Cell. Biochem. 57 (1995) 341-350
80. Oshima O., Leboy P.S., McDonald S.A., Tuan R.S., and Shapiro I.M. Developmental expression of genes in chick growth cartilage detected by in situ hybridization. Calc. Tissue Int. 45 (1989) 182-192
81. Paley P.J., Goff B.A., Gown A.M., Greer B.E., and Sage E.H. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gyn. Oncol. 78 (2000) 336-341
82. Polette M., Nawrocki-Raby B., Gilles C., Clavel C., and Birembaut P. Tumour invasion and matrix metalloproteinases. Crit. Rev. Oncol. Hematol. 49 (2004) 179-186
83. Porter P.L., Sage E.H., Lane T.F., Funk S.E., and Gown A.M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43 (1995) 791-800
84. Prada F., Benedetti L.G., Bravo A.I., Alvarez M.J., Carbone C., and Podhajcer O.L. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J. Invent. Dermatol. 127 (2007) 2618-2628
85. Puolakkainen P.A., Brekken R.A., Muneer S., and Sage E.H. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2 (2004) 215-224
86. Raines E.W., Lane T.F., Iruela-Arispe M.L., Ross R., and Sage E.H. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 1281-1285
87. Reed M.J., Puolakkainen P., Lane T.F., Dickerson D., Bornstein P., and Sage E.H. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem. 41 (1993) 1467-1477
88. Rempel S.A., Golembieski W.A., Ge S., Lemke N., Elisevich K., Mikkelsen T., and Gutierrez J.A. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J. Neuropathol. Exp. Neurol. 57 (1998) 1112-1121
89. Rempel S.A., Golembieski W.A., Fisher J.L., Maile M., and Nakeff A. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J. Neuro-oncol. 53 (2001) 149-160
90. Rodriguez-Jimenez F.J., Caldes T., Iniesta P., Vidart J.A., Garcia-Asenjo J.L., and Benito M. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncol. Rep. 17 (2007) 1301-1307
91. Sage E.H., and Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondi. J. Biol. Chem. 266 (1991) 14831-14834
92. Sage H., Johnson C., and Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J. Biol. Chem. 259 (1984) 3993-4007
93. Sage E.H., Bassuk J.A., Yost J.C., Folkman M.J., and Lane T.F. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J. Cell. Biochem. 57 (1995) 127-140
94. Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P., et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J. Biol. Chem. 278 (2003) 37849-37857
95. Said N., and Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am. J. Pathol. 167 (2005) 1739-1752
96. Said N., Najwer I., and Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am. J. Pathol. 170 (2007) 1054-1063
97. Said N., Socha M.J., Olearczyk J.J., Elmarakby A.A., Imig J.D., and Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res. 5 (2007) 1015-1030
98. Said N., Najwer I., Socha M.J., Fulton D.J., Mok S.C., and Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9 (2007) 23-35
99. Salonen J., Domenicucci C., Goldberg H.A., and Sodek J. Immunohistochemical localization of SPARC (osteonectin) and denatured collagen and their relationship to remodelling in rat dental tissues. Arch. Oral Biol. 35 (1990) 337-346
100. Sangaletti S., Stoppacciaro A., Guiducci C., Torrisi M.R., and Colombo M.P. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J. Exp. Med. 198 (2003) 1475-1485
101. Sansom O.J., Mansergh F.C., Evans M.J., Wilkins J.A., and Clarke A.R. Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut 56 (2007) 1410-1414
102. Sato H., and Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J. Biochem. 119 (1996) 209-215
103. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., and Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370 (1994) 61-65
104. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G.H., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22 (2003) 5021-5030
105. Schultz C., Lemke N., Ge S., Golembieski W.A., and Rempel S.A. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res. 62 (2002) 6270-6277
106. Schwarzbauer J.E., and Spencer C.S. The Caenorhabditis elegans homologue of the extracellular calcium binding protein SPARC/osteonectin affects nematode body morphology and mobility. Mol. Biol. Cell 4 (1993) 941-952
107. Shankavaram U.T., DeWitt D.L., Funk S.E., Sage E.H., and Wahl L.M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell. Physiol. 173 (1997) 327-334
108. Shi Q., Bao S., Maxwell J.A., Reese E.D., Friedman H.S., Bigner D.D., Wang X.F., and Rich J.N. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J. Biol. Chem. 279 (2004) 52200-52209
109. Shi Q., Bao S., Song L., Wu Q., Bigner D.D., Hjelmeland A.B., and Rich J.N. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26 (2007) 4084-4094
110. Shimada H., Chatten J., Newton Jr. W.A., Sachs N., Hamoudi A.B., Chiba T., Marsden H.B., and Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst. 73 (1984) 405-416
111. Smid M., Dorssers L.C., and Jenster G. Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics 19 (2003) 2065-2071
112. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., Lieber A., and Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol. Biomark. Prev. 15 (2006) 114-123
113. Stetler-Stevenson W.G. Progelatinase A activation during tumor cell invasion. Invas. Metast. 14 (1994) 259-268
114. Strongin A.Y., Marmer B.L., Grant G.A., and Goldberg G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. 268 (1993) 14033-14039
115. Suzuki M., Hao C., Takahashi T., Shigematsu H., Shivapurkar N., Sathyanarayana U.G., et al. Aberrant methylation of SPARC in human lung cancers. Br. J. Cancer 92 (2005) 942-948
116. Swaroop A., Hogan B.L., and Francke U. Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics 2 (1988) 37-47
117. Taghizadeh F., Tang M.J., and Tai I.T. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol. Cancer Ther. 6 (2007) 309-317
118. Tai I.T., Dai M., Owen D.A., and Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 115 (2005) 1492-1502
119. Tang M.J., and Tai I.T. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem. 282 (2007) 34457-34467
120. Termine J.D., Kleinman H.K., Whitson S.W., Conn K.M., McGarvey M.L., and Martin G.R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26 (1981) 99-105
121. Teschendorff A.E., Miremadi A., Pinder S.E., Ellis I.O., and Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8 (2007) R157
122. Thomas R., True L.D., Bassuk J.A., Lange P.H., and Vessella R.L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. 6 (2000) 1140-1149
123. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8681-8686
124. Tremble P.M., Lane T.F., Sage E.H., and Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol. 121 (1993) 1433-1444
125. Vajkoczy P., Menger M.D., Goldbrunner R., Ge S., Fong T.A., Vollmar B., et al. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int. J. Cancer 87 (2000) 261-268
126. Van Hensbergen Y., Broxterman H.J., Hanemaaijer R., Jorna A.S., van Lent N.A., Verheul H.M.W., Pinedo H.M., and Hoekman K. Soluble aminopeptidase N/CD13 in malignant and nomalignant effusions and intratumoral fluid. Clin. Cancer Res. 8 (2002) 3747-3754
127. Van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
128. Vial E., and Castellazzi M. Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo. Oncogene 19 (2000) 1772-1782
129. Von Hoff, D.D., Borad, M., Ramanathan, R.K., Smith, L.S., Drengler, R.L., Wood, T.E., Laheru, D., Hedalgo, M., 2008. Promising clinical activity of a NAB pacitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer (Abstracts 4179). In: Proceedings of the 99th Annual Meeting, April 12-16, 2008. Am. Assoc. Cancer Res, San Diego, CA.
130. Wang Y., Yu Q., Cho A.H., Rondeau G., Welsh J., Adamson E., Mercola D., and McClelland M. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7 (2005) 748-760
131. Watkins G., Douglas-Jones A., Bryce R., Mansel R.E., and Jiang W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglan. Leukotr. Essent. Fatty Acids 72 (2005) 267-272
132. Welsh J.B., Sapinoso L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61 (2001) 5974-5978
133. Wewer U.M., Albrechtsen R., Fisher L.W., Young M.F., and Termine J.D. Osteonectin/ SPARC/BM-40 in human decidua and carcinoma, tissues characterized by de novo formation of basement membrane. Am. J. Pathol. 132 (1988) 345-355
134. Wiese A.H., Auer J., Lassmann S., Nahrig J., Rosenberg R., Hofler H., Ruger R., and Werner M. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect. Prevent. 31 (2007) 282-295
135. Wong S.Y., Haack H., Kissil J.L., Barry M., Bronson R.T., Shen S.S., et al. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12784-12789
136. Wong S.Y., Crowley D., Bronson R.T., and Hynes R.O. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin. Exp. Metast. 25 (2008) 109-118
137. Yabushita H., Shimazu M., Noguchi M., Kishida T., Narumiya H., Sawaguchi K., and Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol. Rep. 10 (2003) 89-95
138. Yan Q., and Sage E.H. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47 (1999) 1495-1506
139. Yang E., Kang H.J., Koh K.H., Rhee H., Kim N.K., and Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int. J. Cancer 121 (2007) 567-575
140. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., and Mok S.C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159 (2001) 609-622
141. Young M.F., Bolander M.E., Day A.A., Ramis C.I., Robey P.G., Yamada Y., and Termine J.D. Osteonectin mRNA: distribution in normal and transformed cells. Nucleic Acids Res. 14 (1986) 4483-4497